<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-102382</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Retrospective Study of Patients Diagnosed With Sweet Syndrome in the Health Area of a Tertiary Hospital in the Autonomous Community of Valencia</dc:title>
<dc:description xml:lang="en">Sweet syndrome is the most characteristic of the neutrophilic dermatoses. We performed a retrospective study of patients with Sweet syndrome seen in our department between 2001 and 2009, inclusive; the aims were to define the patient profile and to evaluate the clinical and epidemiological differences between subgroups. There were 24 patients (13 women and 11 men). The age distribution was similar in both sexes and showed 2 peaks, one in the fourth decade and the other in the eighth decade. The etiology was predominantly infectious or inflammatory, followed by the idiopathic form. There were 4 cases of paraneoplastic disease, 2 of which involved solid-organ tumors. One case was associated with the administration of infliximab. Symptoms persisted longer in cases that were idiopathic or that developed in the context of neoplastic disease (AU)</dc:description>
<dc:creator>Díaz-Corpas, T</dc:creator>
<dc:creator>Mateu-Puchades, A</dc:creator>
<dc:creator>Morales-Suárez-Varela, M. M</dc:creator>
<dc:creator>Castells-Rodellas, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome de Sweet (SS) es la más característica de todas las dermatosis neutrofílicas. Para definir el perfil de los pacientes diagnosticados de SS en nuestro Departamento y evaluar las diferencias clínico-epidemiológicas entre subgrupos, hemos realizado un estudio retrospectivo desde 2001 a 2009, ambos inclusive. Han sido incluidos 24 pacientes (13 mujeres y 11 hombres). La distribución por edades es similar en todos los grupos con dos picos: entre los 30-39 y los 70-79 años. Respecto a la etiología predomina el grupo que incluye los casos infecciosos e inflamatorios, seguido del grupo de etiología idiopática. De los 4 casos paraneoplásicos dos correspondían a neoplasias de órganos sólidos. Hay un caso asociado a la administración de infliximab. En cuanto a la evolución existe una mayor duración de la sintomatología en los casos paraneoplásicos e idiopáticos (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;103(3): 233-237, abr. 2012.</dc:source>
<dc:identifier>ibc-102382</dc:identifier>
<dc:title xml:lang="es">Estudio retrospectivo de pacientes diagnosticados de síndrome de Sweet en el área de un hospital terciario de la Comunidad Valenciana</dc:title>
<dc:subject>^d10445^s22057</dc:subject>
<dc:subject>^d10445^s22012</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d10445^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d29797^s22032</dc:subject>
<dc:subject>^d29797^s22012</dc:subject>
<dc:subject>^d29797^s22067</dc:subject>
<dc:subject>^d29797^s22016</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d13252^s22012</dc:subject>
<dc:subject>^d10445^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201204</dc:date>
</metadata>
</record>
</ibecs-document>
